Affordable, quality health care. For everyone.

Bundled-Payment Models Around the World: How They Work and What Their Impact Has Been

Downloads

Abstract

  • Issue: Understanding the impact of bundled-payment models on value in health care requires a better understanding of how design choices and implementation strategies affect cost and quality.
  • Goal: To describe the key design elements of bundled-payment models and evaluate empirical evidence about their impact on quality of care and medical spending.
  • Methods: Scan of the scientific and grey literature.
  • Findings and Conclusions: We identified 23 initiatives in eight countries that have implemented bundled-payment models, focusing on procedures such as total joint replacements and cardiac surgery, as well as chronic conditions like diabetes and breast cancer. Of the 35 studies retrieved, 32 reported effects on quality of care and 32 reported effects on medical spending. Twenty of 32 studies reported modest savings or a modest reduction in spending growth, while two studies (both based on the same initiative) demonstrated increased spending in the early years of the bundled-payment model’s implementation. Eighteen of 32 studies reported quality improvements for most evaluated measures, while other studies showed no difference in measured quality. Our study provides evidence that bundled-payment models have the potential to reduce medical spending growth while having either a positive impact or no impact on quality of care.

Background

Public and private payers around the globe are increasingly shifting away from fee-for-service (FFS) payment models in favor of alternative payment models (APMs) that give providers incentives to improve value. The rationale is that providers and organizations are in the best position to identify ways to reduce waste and overuse, coordinate care across settings, steer patients to the most appropriate, high-quality providers, and provide needed care.

APMs vary in design. Some, such as accountable care organizations and Gesundes Kinzigtal, target total population spending, while others focus on creating incentives for providers to limit spending during episodes, or bundles, of care.1 These later models go by many names — including episode-based payment, episode payment, episode-of-care payment, case rate, evidence-based case rate, and global bundled payment. What they have in common is a shift of financial and clinical risk from payers to providers.

Bundled-payment models capitalize on the provider entity’s need to manage a budget and ensure quality. The entity receiving the bundled payment earns a higher margin if a patient utilizes less care, but also must cover the cost of unexpected utilization and complications. Public and private payers in many countries are implementing APMs on the theory that giving care providers a financial stake in driving value might be more effective than asking patients to assume financial risk through deductibles, co-payments, and out-of-pocket payments.2

To gain a better understanding of the impact of design choices and implementation strategies, this study aimed to: 1) provide an overview of current bundled-payment models in high-income countries; and 2) describe the key design elements of bundled-payment models and estimate their effects on quality of care and medical spending.

How Do Bundled-Payment Models Work in Practice?

We systematically analyzed bundled-payment model initiatives by describing the general characteristics of the initiative — including country, year of implementation, what condition (or conditions) it covers, and whether the model was a pilot or fully implemented — and the key design elements of the bundled payment, such as target population, included care components, and payment methodology. We assessed payment methodology using an adaptation of the HCP-LAN framework by De Vries and colleagues that looks at receiving entity, time period, risk-adjustment methods, distribution among participating providers, and link with quality.3

General Characteristics

We identified 23 bundled-payment initiatives across eight high-income countries (Exhibit 1). Most of the initiatives were introduced in the United States (n=15), but we also studied programs in Taiwan, England (n=2), the Netherlands, Portugal, Denmark, New Zealand, and Sweden. The earliest initiative was implemented in Taiwan in 2001, followed by several in European countries in 2007 (the Netherlands and Denmark) and 2008 (Portugal). Substantial uptake of bundled-payment models occurred in the U.S. after the introduction of the Affordable Care Act.

Most initiatives focus on one condition, procedure, or treatment. Most payment models in this study started with only one chronic condition, procedure, or treatment, such as diabetes (the Netherlands and Denmark), maternity care (U.S. and England), end-stage renal disease (Portugal and U.S.), breast cancer (Taiwan and U.S.), or total joint replacement (U.S. and Sweden). Some of the bundles target a range of related conditions, such as the U.S. oncology bundles that include multiple forms of cancer. Four other initiatives include multiple conditions or procedures in their bundled-payment model. The Bundled Payment for Care Improvement (BPCI), a U.S. pilot, includes the broadest range, with 48 chronic conditions or episodes.

Finally, one initiative (England’s long-term care model) does not focus on a specific condition or treatment but integrates the payment models of services from different domains, such as long-term care and social care. The payment applies to the whole population, irrespective of disease, condition, or procedure. This payment model could be characterized as partial global payment instead of a bundled payment, which we define as an episode of care for a medical condition or treatment including services of multiple providers.

Most bundled-payment models started as pilots but have been permanently implemented. All initiatives started with pilot programs and evolved toward permanent implementation. Some of the experimental bundled-payment models had a formal end date but lived on in newly launched bundled-payment models with new names. For instance, the Acute Care Episode payment model formally ended but contributed to the creation of the BPCI.

All bundled-payment models were voluntary with the exception of England’s Maternity Pathway Bundled Payment model and the Arkansas Payment Improvement Initiative. The U.S. Comprehensive Care for Joint Replacement Payment model was initially designed to be mandatory but was implemented as a voluntary program so that more input could be collected.4

Key Design Elements

Exhibit 2 summarizes design features of bundled-payment models. (For specific features of each of the 23 initiatives, see Appendix.)

Included care services were quite comparable within specific conditions. Across the initiatives using a bundled-payment model for the same condition, the included care services were similar, irrespective of country. For instance, maternity care initiatives from the U.S. (Horizon Blue Cross, Arkansas Payment Improvement Initiative), New Zealand (Leading Maternity Carer), and England (Maternity Pathway Bundled Payment) all included prenatal, natal, and postnatal services. The same holds for initiatives focused on total joint arthroplasty (TJA).

All the TJA initiatives included the surgery itself, the prosthesis, and postdischarge care services including readmissions and complications. In Sweden, Orthochoice also included a presurgical visit, which was not the case in the other TJA models. In addition, included care services for most bundles were limited to a single care sector, with the exception of England’s long-term care bundled-payment model, which included both health care and social care. In general, no preventive services were included in the bundles.

Definition of episode differed among conditions. Bundled-payment models focusing on a chronic condition generally defined a care episode as a calendar time period. For example, in both diabetes care bundles (Netherlands and Denmark), a care episode is 365 days. Bundles that cover a procedure or treatment such as a total joint replacement (TJR) defined their episode of care as the period of illness or care cycle. In the TJR bundles, this episode included a preoperative period, an inpatient period, and a postdischarge period, with the length of these periods varying. TJA bundles vary widely in how they quantify episodes: In the BPCI model, the postdischarge period is maximized at 180 days; in the Swedish model this period was two years with an extension to five years if a complication occurred within the first two years.

Both retrospective and prospective bundled-payment models were applied. Payers and providers choose from two main strategies for payment flow, namely 1) a prospectively established price that is paid as one payment to the accountable entity; or 2) upfront FFS payments to individual providers within the episode with a retrospective reconciliation period. Among the bundled-payment initiatives studied, 10 initiatives used a retrospective bundled-payment model, while 12 chose a prospective bundled-payment model. One initiative (BPCI) included both retrospective and prospective payment models.

Risk-sharing properties, risk-adjustment methods, distribution, and link with quality were not well-described in many initiatives. Among the research papers and reports on bundled-payment initiatives, the risk-sharing properties, risk adjustment methods, and distribution of pay for the included care services were not described or only briefly described.

What Does Empirical Evidence Show About the Impact of Bundled-Payment Models?

About half of the bundled-payment initiatives were empirically evaluated. In total, we retrieved 35 papers evaluating 11 bundled-payment initiatives. To our knowledge, the 12 additional initiatives in our study have not generated publicly available empirical evidence on their impact on quality of care and medical spending. Most studies were on the U.S. bundled-payment models, of which the BPCI was most commonly evaluated. All studies had an observational design and the most commonly applied methodologies were pre- and post-measurement without a control group, or difference-in-difference approach (that is, pre- and post-measurement with a control group). Of the 35 retrieved papers, 32 reported effects of the bundled-payment model on quality of care; 32 reported the effects of the bundled-payment model on medical spending; and no papers reported the effects of the payment model on accessibility.

Most studies reported positive (cost-saving) effects of bundled-payment models on medical spending. Twenty of the 32 studies that evaluated the effects of the bundled-payment model on medical spending reported lower medical spending and/or spending growth as compared to their control group. The effect varied widely between studies. For example, Sweden’s bundled-payment model for total hip and total knee replacements yielded a decrease of 34 percent in total average medical spending, while a U.S. initiative targeting chronic obstructive pulmonary disease in Medicare patients reported a 4.3 percent cost savings compared with BPCI target prices.5 The only initiative in which an increase in medical spending was observed was the Dutch bundled-payment model for diabetes care. Within this model, total medical spending increased in the first two years.6 Evaluations on long-term effects of the Dutch diabetes bundled-payment model are not available.

Eighteen studies reported positive effects on quality of care, while two studies reported negative effects. Among the 32 papers that reported on the effect of the initiative on quality of care, 18 reported overall (small) positive effects on the quality of care measures, while in 12 studies no (significant) quality improvements were demonstrated. Some of these 12 studies had mixed results: Some quality measures were slightly positive while others were unchanged. Two of the studies reported negative effects on the quality of care delivered.

Both process and outcome measures were included in all studies. Many of the process measures were focused on guideline adherence, like the percentage of patients receiving necessary checkups. No differences were found in the effect on process or outcome measures. If positive effects were reported, it was mostly observed in both process and outcome measures.

Patient experiences were not regularly evaluated within the obtained studies. Patient experiences were rarely measured in the 35 studies. One study reported a higher likelihood to recommend the surgeon within the bundled-payment group (94.4%) as compared to the overall average percentage (76.0%).7

Exhibit 3 presents selected findings from the studies showing how bundled-payment models affected quality of care and cost. (For additional findings of each of the 23 initiatives, see Appendix.)

Discussion

Bundled payments have had a predominantly positive effect on medical spending and quality of care. Bundled-payment models have had predominantly positive impacts on both spending and quality of care, irrespective of country, medical procedure, or condition and applied research methodology. Twenty out of 32 studies reported lower medical spending or spending growth, and 18 studies reported quality of care improvements. Remarkably, just two (6%) studies produced negative outcomes.

Moreover, the a priori assumed effects of bundled-payment models were supported by multiple evaluation studies, although most of the studies had design weaknesses that limited causal inference. Bundled-payment models have led to closer collaboration among providers, better coordination of care, reduction of low-value care services and overuse of care, and greater use of preventive services.

Voluntary bundled-payment initiatives might have led to selection. Because the majority of initiatives introduced bundled payments on a voluntary basis, selection bias may have affected the results. For instance, providers and organizations who choose to implement bundled payments may be more able to implement and more likely to benefit from this payment model.8 Providers and organizations that expect not to benefit may be more reluctant to switch to the bundled-payment model. In addition, in most cases there were no penalties for dropping out of the initiatives. Within the U.S. BPCI model, a substantial share of providers and organizations dropped out of the program.9 In studies from other countries, this phenomenon of dropouts was not mentioned.

Should bundled payments be retrospective or prospective? One of the most discussed issues of bundled-payment models focuses on the timing of the payment flow: Should bundles be paid prospectively or retrospectively? The studies suggest that the difference between retrospective and prospective payments is not significant in practice, particularly because retrospective payments are often based on up-front negotiated benchmarks.10

In addition, “loss aversion” acts as an incentive to include downside risk in retrospective bundled payments, as a way of mimicking the incentives created by prospective bundled payments. Research suggests that the natural aversion to loss is why an upfront negotiated benchmark will never adequately mimic the incentives from a prospective payment. Furthermore, assuming downside risk in a retrospective payment arrangement results in physicians behaving differently than if they had assumed full financial accountability for managing a prospective bundled payment.11 More research should be done to better understand the effects of payment timing on provider behavior.

Cross-national learning will be crucial for the implementation of bundled payments. The challenge of implementing bundled-payment models is a recurring theme in the scientific literature.12 Some operational hurdles are relatively well-known, such as privacy laws that affect information-sharing, the difficulty of defining quality criteria, and “gaming.”13 Other challenges are less well-described, such as difficulties identifying which patients are included in the bundle, income loss for some care professionals, and potential limits on patients’ freedom of choice.14 These challenges point to a need for more insight into barriers to implementation. The various ways that bundled-payment models have been operationalized — and the difficulties both payers and providers have experienced so far — make clear that shifting from FFS toward bundled payments is not a simple or straightforward process. As bundled-payment models continue to take root in multiple countries, learning from their successes and failures will be critical.


Notes

1. J. M. McWilliams, “Savings from ACOs-Building on Early Success,” Annals of Internal Medicine 165, no. 12 (Dec. 2016): 873–75; Z. Song et al., “Health Care Spending and Quality in Year 1 of the Alternative Quality Contract,” New England Journal of Medicine 365, no. 10 (Sept. 2011): 909–18; A. Pimperl et al., “Evaluating the Impact of an Accountable Care Organization on Population Health: The Quasi-Experimental Design of the German Gesundes Kinzigtal,” Population Health Management 20, no. 3 (2017): 239–48; and K. Baicker and M. E. Chernew, “Alternative Alternative Payment Models,” JAMA Internal Medicine 177, no. 2 (Feb. 2017): 222–23.

2. Baicker and Chernew, “Alternative Alternative,” 2017.

3. R. K. Wadhera, R. W. Yeh, and K. E. Joynt Maddox, “The Rise and Fall of Mandatory Cardiac Bundled Payments,” JAMA 319, no. 4 (Jan. 2018): 335–36; and E. F. De Vries et al., “Barriers to Payment Reform: Experiences from Nine Dutch Population Health Management Sites,” (under review).

4. Wadhera, Yeh, and Joynt Maddox, “Rise and Fall,” 2018.

5. R. Busse and J. Stahl, “Integrated Care Experiences and Outcomes in Germany, the Netherlands, and England,” Health Affairs 33, no. 9 (Sept. 2014): 1549–58; J. P. Doran et al., “Implementation of Bundled Payment Initiatives for Total Joint Arthroplasty: Decreasing Cost and Increasing Quality,” Instructional Course Lectures 65 (2016): 555–66; and F. de Brantes and S. F. Delbanco, “The Payment Reform Landscape: Is The Debate Over Retrospective Versus Prospective Bundled Payments A Distraction?,” Health Affairs Blog, June 23, 2017.

6. S. Mohnen, C. Baan, and J. Struijs, “Bundled Payments for Diabetes Care and Healthcare Costs Growth: A 2-Year Follow-up Study,” American Journal of Accountable Care (Dec. 2015); and Busse and Stahl, “Integrated Care Experiences,” 2014.

7. Wadhera, Yeh, and Joynt Maddox, “Rise and Fall,” 2018.

8. Wadhera, Yeh, and Joynt Maddox, “Rise and Fall,” 2018.

9. Wadhera, Yeh, and Joynt Maddox, “Rise and Fall,” 2018.

10. De Brantes and Delbanco, “Payment Reform Landscape,” 2017.

11. K. van der Swaluw, J. N. Struijs, and A. P. Hayen, “When Designing Bundled Payments: Don’t Ignore the Lessons of Behavioral Economics,” Health Affairs Blog, Apr. 2018.

12. T. Shih, L. M. Chen, and B. K. Nallamothu, “Will Bundled Payments Change Health Care? Examining the Evidence Thus Far in Cardiovascular Care,” Circulation 131, no. 24 (2015): 2151–58.

13. D. A. Conrad, “The Theory of Value-Based Payment Incentives and Their Application to Health Care,” Health Services Research 50, suppl. 2 (Dec. 2015): 2057–89: D. A. Conrad et al., “Emerging Lessons from Regional and State Innovation in Value-Based Payment Reform: Balancing Collaboration and Disruptive Innovation,” Milbank Quarterly 92, no. 3 (Sept. 2014): 568–623; and D. A. Conrad et al., “Implementing Value-Based Payment Reform: A Conceptual Framework and Case Examples,” Medical Care Research and Review 73, no. 4 (Aug. 2016): 437–57.

14. S. S. Steenhuis et al., “Unraveling the Complexity in the Design and Implementation of Bundled Payments: A Scoping Review Based Framework of Key Elements from a Payer’s Perspective,” accepted Milbank Quarterly.

Publication Details

Publication Date: April 6, 2020
Contact: Jeroen Struijs, 2013-14 Harkness Fellow
Senior Researcher and Project Leader
Centre of Prevention and Health
National Institute of Public Health and the Environment
Citation:

Jeroen N. Struijs et al., Bundled-Payment Models Around the World: How They Work and What Their Impact Has Been (Commonwealth Fund, Apr. 2020). https://doi.org/10.26099/936s-0y65

Experts

2013-14 Harkness Fellow
Senior Researcher and Project Leader
Centre of Prevention and Health
National Institute of Public Health and the Environment
Researcher, RIVM National Institute for Public Health and the Environment
Chief Science Officer, RIVM National Institute for Public Health and the Environment
Researcher, RIVM National Institute for Public Health and the Environment
C. Boyden Gray Professor of Health Economics and Policy, Harvard T.H. Chan School of Public Health